Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Thomas Graney sold 777 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $149.95, for a total transaction of $116,511.15. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $153.07 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. Vertex Pharmaceuticals Incorporated has a 1 year low of $76.15 and a 1 year high of $167.85. The stock has a market cap of $38,443.75, a P/E ratio of 196.25, a price-to-earnings-growth ratio of 1.92 and a beta of 1.58.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. During the same quarter last year, the company earned $0.16 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 39.7% on a year-over-year basis. equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.
Several research analysts have recently weighed in on VRTX shares. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. DA Davidson started coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Sunday, September 17th. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Finally, Deutsche Bank started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-five have given a buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and an average target price of $173.78.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.